Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.

Last updated on 15-12-2021 by Cyril Barbezange



BACKGROUND: Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥⅓20 was the product of choice for the stu…

Associated health topics:

QR code

QR code for this page URL